Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission

This is a multi-centre, randomised, controlled, investigator blinded study. The randomisation will be done centrally. The patients will be treated for 1 year, with clinical and laboratory assessments at 0, 4, 8 and 12 months.

Endoscopic examination is at enrollment and on completion of the study (at relapse or after 12 months).

Number of Subjects (Planned and Analysed):

* 360 patients for demonstration of non-inferiority between once daily and twice daily; * 326 to be analysed in per-protocol (PP) analyses; and * 360 in intention-to-treat (ITT) analyses.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ulcerative Colitis Colitis Colitis, Ulcerative Colonic Diseases Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hôpital Erasme Unité de Recherche, Clinique Gastro-entérologie, Brussels, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients have an established diagnosis of ulcerative colitis and are in clinical remission with an UC-DAI < 2 at enrollment
Extension of the disease > 15 cm distance from anal verge
Patients who have had a clinical relapse within the past year. Clinical relapse is defined as activity of the disease for which maintenance therapy had to be adjusted.
Patients on oral mesalazine maintenance therapy ≤ 2.5 grams per day
18 years or older
Signed informed consent

Exclusion criteria

Patients with evidence of other forms of inflammatory bowel disease, idiopathic proctitis or infectious disease
Patients allergic to acetylsalicylic acid and other salicylate derivates aspirin or salicylates derivatives
Patients who used mesalazine > 2.5 grams orally in the previous month,
Patients who used rectal mesalazine > 3 grams per week in the previous month
Use of corticosteroids (oral and/or rectal routes) within the last month
Intake of immunosuppressants within the last 3 months
Patients with (known) significant hepatic (up to 2 x upper limit of normal) or (known) renal function abnormalities, to 1.5 x upper limit of normal values
Patients with history or physical examination findings indicative of active alcohol or drug abuse
Patients with a history of disease, including mental/emotional disorders, that would interfere with their participation in the study
Women who are pregnant or nursing (non-menopausal women who are sexually active and do not use effective contraceptives, as judged by the investigator, must have a negative pregnancy test)
Patients who participated in another clinical study in the last 3 months
Patients who were previously participating in this study
Patients with any other disease that may influence the study assessment, such as malignant disease, etc.
Patients who are unable to comply with any requirements of the protocol
Patients who are unable to write or read local language.

Treatment and study plan

Pentasa

Drug

Sponsors and collaborators

Lead sponsor

Ferring Pharmaceuticals

Industry

Registry information

Official study title

Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission. A European Multi-centre Investigator Blinded Randomized Controlled Study of Pentasa Sachet Comparing One Gram Twice With Two Grams Once Daily

Important dates

Study start: 2005
Primary completion: 2007
Study completion: 2007
First posted: Sep 21, 2005
Registry last updated: May 19, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed